1. Home
  2. SRRK vs BXSL Comparison

SRRK vs BXSL Comparison

Compare SRRK & BXSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Scholar Rock Holding Corporation

SRRK

Scholar Rock Holding Corporation

HOLD

Current Price

$47.49

Market Cap

6.8B

Sector

Health Care

ML Signal

HOLD

Logo Blackstone Secured Lending Fund of Beneficial Interest

BXSL

Blackstone Secured Lending Fund of Beneficial Interest

HOLD

Current Price

$23.17

Market Cap

5.5B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
SRRK
BXSL
Founded
2012
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
6.8B
5.5B
IPO Year
2018
2018

Fundamental Metrics

Financial Performance
Metric
SRRK
BXSL
Price
$47.49
$23.17
Analyst Decision
Strong Buy
Buy
Analyst Count
13
10
Target Price
$56.17
$27.18
AVG Volume (30 Days)
1.0M
1.6M
Earning Date
05-07-2026
05-07-2026
Dividend Yield
N/A
12.87%
EPS Growth
N/A
N/A
EPS
N/A
0.11
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$534.24
N/A
P/E Ratio
N/A
$210.00
Revenue Growth
N/A
N/A
52 Week Low
$27.07
$22.47
52 Week High
$58.49
$31.24

Technical Indicators

Market Signals
Indicator
SRRK
BXSL
Relative Strength Index (RSI) 39.11 44.60
Support Level $45.83 $22.47
Resistance Level $48.23 $24.84
Average True Range (ATR) 2.20 0.42
MACD -0.65 -0.03
Stochastic Oscillator 5.15 23.94

Price Performance

Historical Comparison
SRRK
BXSL

About SRRK Scholar Rock Holding Corporation

Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.

About BXSL Blackstone Secured Lending Fund of Beneficial Interest

Blackstone Secured Lending Fund is a non-diversified, closed-end management investment company. The investment objectives of the company are to generate current income and, to a lesser extent, long-term capital appreciation. The company seeks to achieve its investment objectives by investing in originated loans and other securities, including syndicated loans of private U.S. companies, typically in the form of first lien senior secured and unitranche loans, unsecured and subordinated loans, and other securities. The company operates as a single reportable segment and derives revenues from investing in originated loans and other securities, including broadly syndicated loans, of U.S. private companies.

Share on Social Networks: